In short
This article discusses the ongoing clinical trials of Lovo-A, a component of the innovative immunotherapy drug STC-1010. The trials aim to evaluate the safety and effectiveness of this treatment for patients with advanced or metastatic colorectal cancer. STC-1010 is being tested in combination with standard-of-care therapies to potentially improve outcomes for patients with this challenging disease.
At a glance
- Drug Name
- STC-1010 (including Lovo-A)
- Type of Treatment
- Immunotherapy (Cell therapy)
- Target Condition
- Unresectable locally advanced or metastatic colorectal cancer
- Trial Phase
- Phase I/IIA
- Main Objectives
- Assess safety, determine optimal dose, evaluate efficacy
- Combination Therapy
- Used with standard chemotherapy (mFOLFOX6) and bevacizumab
- Patient Groups
- MSS/pMMR and MSI-H/dMMR colorectal cancer patients
- Primary Endpoint
- Progression-free survival rate at 12 months (Phase IIA)
What is LOVO-A?
LOVO-A is an innovative immunotherapy treatment being studied for patients with advanced colorectal cancer. It is part of a new drug called STC-1010, which is a combination of different cell therapies. LOVO-A is one of the six active substances in STC-1010, along with HCT116-A, HCT116-B, HT-29-A, HT-29-B, and LOVO-B.
Medical Conditions Treated
LOVO-A, as part of STC-1010, is being studied to treat unresectable locally advanced or metastatic colorectal cancer. This means it's intended for patients whose cancer: Has spread to nearby tissues or lymph nodes and cannot be completely removed by surgery (locally advanced) Has spread to distant parts of the body (metastatic) Cannot be surgically removed (unresectable)
How LOVO-A Works
LOVO-A is a type of cell therapy, which is an advanced form of treatment that uses cells to fight diseases. In this case, LOVO-A is derived from colorectal cancer cells. The idea behind this treatment is to stimulate the patient's immune system to recognize and attack cancer cells more effectively.
STC-1010, which includes LOVO-A, is given as a solution for injection, typically administered into the skin (intradermal injection). It's used in combination with other cancer treatments to potentially enhance their effectiveness.
Clinical Trial Details
LOVO-A is currently being studied in a clinical trial called the BreAK CRC trial. This trial has two main parts:
- Phase I: This part focuses on finding the right dose and checking the safety of STC-1010 when given with standard cancer treatments.
- Phase IIA: This part looks at how well STC-1010 works in treating colorectal cancer when combined with standard treatments.
The trial is testing STC-1010 (which includes LOVO-A) in combination with other cancer drugs like mFOLFOX6 (a chemotherapy combination) and bevacizumab (a targeted therapy).
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key points include:
- Age between 18-75 years
- Diagnosed with unresectable locally advanced or metastatic colorectal cancer
- Good overall health status
- No active autoimmune diseases or severe infections
There are additional specific criteria for different parts of the study. Your doctor can provide more detailed information about eligibility.
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to consider:
Potential Benefits:
- Access to a new treatment that might be more effective than standard therapies
- Close monitoring by healthcare professionals
- Contributing to medical research that could help future patients
Potential Risks:
- Unknown side effects
- The treatment may not be effective for everyone
- Time commitment for medical visits and procedures
It's important to discuss these potential benefits and risks thoroughly with your healthcare provider before considering participation in the clinical trial.